Short answer
CYTOKINETICS INC (CYTK) filed its fiscal 2025 10-K annual report with the SEC on Feb 26, 2026. It reported revenue of $88M (+376.6% year over year) and net income of −$785M.
- Top risk flagged: Cybersecurity risk oversight led by Audit Committee with tech, risk, finance expertise and regular briefings from CISO, CEO, CFO
FY2025 key financial metrics · XBRL
- Revenue
- $88M
- +376.6% YoY
- Net income
- −$785M
- −33.2% YoY
- Operating margin
- -695.4%
- +2207.3 pp YoY
- EPS (diluted)
- −$6.54
- −24.3% YoY
- ROE
- 119.0%
- −316.5 pp YoY
- Operating cash flow
- −$510M
- −28.8% YoY
Source: XBRL data from the CYTOKINETICS INC (CYTK) FY2025 10-K on SEC EDGAR. USD.
CYTOKINETICS INC FY2025 10-K analysis
AI summary of each section, grounded in the filing text
Business Overview
- Core business model: biopharmaceutical development and commercialization focused on muscle biology therapeutics for cardiovascular diseases
- New product launch: MYQORZO approved by FDA in Dec 2025 for symptomatic oHCM, first commercial sales commenced Q1 2026
- Strategic shift: transition from R&D focus to commercial readiness and sales activities for MYQORZO in US and Europe
- Financial metric: cash, cash equivalents, and marketable securities $1.22B (2025), borrowings increased to $1.33B from $805M in 2024
- Noteworthy fact: entered multiple substantial royalty monetization and debt financings including $750M 2031 Notes issuance and renegotiated out-licenses in Greater China and Japan
Management Discussion & Analysis
- Revenue $88.1M in 2025, up $69.6M from $18.5M in 2024, driven by license and milestone revenues from Bayer and Sanofi
- Operating expenses rose sharply: R&D $416.0M (+23% YoY), G&A $284.3M (+32% YoY), reflecting clinical advancement and commercial readiness
- Best segment license/milestone revenues $79.4M in 2025 vs $15.0M in 2024; collaboration revenue $8.7M in 2025 vs $3.5M in 2024
- Cash use in 2025 driven by $100M loan draw, $121.2M debt conversion expense, increased interest expense $45.6M (up $7.9M YoY); expect higher SG&A in 2026 due to commercialization
- Management expects flat to declining R&D in 2026; key risks: regulatory approvals, market acceptance of MYQORZO, limitations from FDA partial clinical hold on CK-089 trial
Risk Factors
- Cybersecurity risk oversight led by Audit Committee with tech, risk, finance expertise and regular briefings from CISO, CEO, CFO
- Dependence on Chief Information Security Officer Eric Brown with 10+ years cybersecurity experience for managing critical security operations
- Cybersecurity incident response plan includes immediate impact mitigation and long-term remediation strategies
- Ongoing Board and Audit Committee dialogue on emerging cybersecurity threats ensures proactive risk governance
- No specific regulatory, geopolitical, operational supply chain, competitive, or financial risks detailed in this section
Generated from the filing text; verify against the original. How to read a 10-K
Ask about this 10-K
Compare years, dig into a risk factor or check the numbers against insider trades and fund holders.